PCI Pharma Services has begun an expansion project with an investment of US$12 million at its Tredegar facility in Wales, UK.
The company is planning to expand the capacity of its drug manufacturing and development capabilities, including both clinical and commercial supply.
The project will also involve doubling the capacity of the contained oral solid dosage form manufacturing facility's large-scale granulation and fluid bed drying capacity.
Moreover, it will even create additional space for new handling capabilities and a small-scale processing area for early-stage non-GMP processing and formulation.
The new space is scheduled to be operational in the first half of 2022.
|PCI Pharma Services